Skip to content

Occipital Transcranial Direct Current Stimulation in Fibromyalgia

Occipital Transcranial Direct Current Stimulation in Fibromyalgia

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00947622
Enrollment
35
Registered
2009-07-28
Start date
2009-07-31
Completion date
2009-11-30
Last updated
2009-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Keywords

Fibromyalgia, Neuromodulation, Transcranial Direct Current Stimulation, Occipital

Brief summary

The aim of this study is to investigate whether transcranial direct current stimulation is effective in the treatment of fibromyalgia related pain. The study provides a placebo arm and the design is a cross-over design.

Interventions

DEVICETranscranial direct current stimulation

Transcranial Direct current stimulation

Sponsors

University Hospital, Antwerp
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients suffering from Fibromyalgia, diagnosed according to the criteria of the ACR-90, with exclusion of other pathologies mimicking the FMS related symptoms by a M.D. of the department of Physical Medicine and Rehabilitation (UZA, Belgium) * Dutch speaking * Stability of medication during the study

Exclusion criteria

* History of substance abuse, unless treated and in remission during 6 months * Cardiac disease, implanted pace-maker or defibrillator * History of epileptic insults * Severe organic comorbidity * Psychiatric comorbidity with psychotic symptoms * Pregnancy

Design outcomes

Primary

MeasureTime frame
Decrease on Visual Analogue Scale (VAS) score for Fibromyalgia related pain and pain scales of the Fibromyalgia Impact Questionnairebaseline, directly after treatment, 3 weeks after treatment

Secondary

MeasureTime frame
Changes in scores of the pain vigilance and awareness questionnaire, pain catastrophizing scale, fibromyalgia impact questionnaire and modified Fatigue Impact Scalebase line, directly after treatment and 3 weeks after treatment

Countries

Belgium

Contacts

Primary ContactMark Plazier, M.D.
mark.plazier@uza.be+32 3 821 3788

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026